Phase 1 Stroke Trial, Recruiting NCT05871606 Sponsor: Wake Forest University Health Sciences Condition: Stroke
Back to Stroke

Phase 1 Stroke Trial, Recruiting

NCT05871606
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 79 years old
  • People who have signs of an acute ischemic (non-bleeding) stroke with a stroke severity score of 6 or higher on a standard medical scale
  • People whose brain CT scan shows an ASPECTS score of 6, which is a measure of how much brain tissue appears healthy on the scan
  • People whose stroke symptoms began less than 16 hours before the start of a clot-removal procedure (called mechanical thrombectomy)
  • People whose CT scan of the blood vessels shows a blockage in a specific major artery on one side of the brain (the MCA M1 or dominant proximal M2 segment)
  • People whose CT perfusion scan (a special scan measuring blood flow) shows a core area of damage less than 70ml, a surrounding at-risk brain tissue area of at least 15ml, and a ratio of at-risk tissue to damaged tissue of 1.8 or greater
  • People who were functioning well before the stroke, with a disability score of 2 or lower on a standard scale
  • People for whom the medical team has already planned to use general anaesthesia (full unconsciousness with a breathing tube) for the clot-removal procedure
  • People, or their authorised representative, who are able to provide consent to participate

Who may not be able to join:

  • People with blood pressure that is too low (below 100/60) or dangerously high (above 185 systolic or 110 diastolic) and unable to be controlled with IV medication
  • People who cannot safely have a brain MRI scan, for example due to having an implanted pacemaker
  • People who received a clot-dissolving medication (tPA) more than 4.5 hours after their stroke symptoms began
  • People with serious blood clotting problems, such as very low platelet counts, high clotting time results, or use of certain blood thinners with significantly reduced kidney function
  • People considered vulnerable, including those who are mentally ill or have reduced decision-making ability, prisoners, people admitted for long-term chronic illness, people who are terminally ill, pregnant women, and children
  • People whose brain CT scan shows any bleeding or a mass (such as a tumour) in the brain
  • People who have had a serious head injury within the past 90 days
  • People with a pre-existing severe brain or psychiatric condition
  • People who had a seizure at the time their stroke started, making it impossible to properly assess stroke severity
  • People with blood sugar levels that are very low (below 50 mg/dL) or very high (above 400 mg/dL)
  • People with a low haemoglobin level (below 7 mmol/L), indicating significant anaemia
  • People with severely reduced kidney function (eGFR below 30 ml/min)
  • People with a known allergy to contrast dye used in scans
  • People whose stroke is thought to have been caused by an infected blood clot (septic embolus)
  • People with significant narrowing or complete blockage of the carotid arteries (the main arteries in the neck or base of the brain) that restricts blood flow

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: William R Stetler, MD, Wake Forest University Health Sciences

Phone: 704-446-0473

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
16 April 2026
Est. completion
1 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Maximum safe dose of iNO for AIS patients - assessing for reperfusion hemorrhage/symptomatic intracranial hemorrhage (sICH)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov